Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 7
2005 2
2006 3
2007 3
2008 11
2009 7
2010 8
2011 10
2012 17
2013 10
2014 9
2015 16
2016 20
2017 16
2018 18
2019 25
2020 25
2021 29
2022 29
2023 23
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.
Strum S, Andersen MH, Svane IM, Siu LL, Weber JS. Strum S, et al. Among authors: svane im. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438592. doi: 10.1200/EDBK_438592. Am Soc Clin Oncol Educ Book. 2024. PMID: 38669611 Review.
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.
Borch A, Carri I, Reynisson B, Alvarez HMG, Munk KK, Montemurro A, Kristensen NP, Tvingsholm SA, Holm JS, Heeke C, Moss KH, Hansen UK, Schaap-Johansen AL, Bagger FO, de Lima VAB, Rohrberg KS, Funt SA, Donia M, Svane IM, Lassen U, Barra C, Nielsen M, Hadrup SR. Borch A, et al. Among authors: svane im. Front Immunol. 2024 Apr 3;15:1360281. doi: 10.3389/fimmu.2024.1360281. eCollection 2024. Front Immunol. 2024. PMID: 38633261 Free PMC article.
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK, Winther ML, Laursen IJ, Madsen FS, Brink C, Brix TH, Ellebaek E, Svane IM, Hansen FS, Haslund C, Laursen OK, Schmidt H, Larsen ID, Bastholt L, Ruhlmann CH. Christensen SK, et al. Among authors: svane im. Support Care Cancer. 2024 Apr 10;32(5):281. doi: 10.1007/s00520-024-08445-y. Support Care Cancer. 2024. PMID: 38598052 Free PMC article.
Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, Hedenfalk I, Yuan J, Nielsen K, Ingvar C, Carneiro A, Isaksson K, Pietras K, Svane IM, Donia M, Jönsson G. Lauss M, et al. Among authors: svane im. Nat Commun. 2024 Apr 9;15(1):3075. doi: 10.1038/s41467-024-47425-y. Nat Commun. 2024. PMID: 38594286 Free PMC article.
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane IM, Sanmamed MF, Gambardella V, McKean M, Callahan M, Dummer R, Klein C, Umaña P, Justies N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack RF, Karanikas V, Fowler S. Spreafico A, et al. Among authors: svane im. Front Oncol. 2024 Mar 21;14:1346502. doi: 10.3389/fonc.2024.1346502. eCollection 2024. Front Oncol. 2024. PMID: 38577337 Free PMC article.
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT, Rohaan MW, Jedema I, Kessels R, Stegeman W, Scheepmaker W, Nuijen B, Nijenhuis C, Lindenberg M, Borch TH, Monberg T, Donia M, Marie Svane I, van Harten W, Haanen J, Retel VP. Ten Ham RMT, et al. Among authors: marie svane i. J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372. J Immunother Cancer. 2024. PMID: 38531663 Free PMC article. Clinical Trial.
Biomarkers for response to TIL therapy: a comprehensive review.
Albarrán Fernández V, Ballestín Martínez P, Stoltenborg Granhøj J, Borch TH, Donia M, Marie Svane I. Albarrán Fernández V, et al. Among authors: marie svane i. J Immunother Cancer. 2024 Mar 13;12(3):e008640. doi: 10.1136/jitc-2023-008640. J Immunother Cancer. 2024. PMID: 38485186 Free PMC article. Review.
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
Homburg S, Christensen CB, Pedersen M, Sørensen SG, Donia M, Svane IM, Hendel HW, Ellebaek E. Homburg S, et al. Among authors: svane im. Cancers (Basel). 2024 Feb 27;16(5):964. doi: 10.3390/cancers16050964. Cancers (Basel). 2024. PMID: 38473325 Free PMC article.
Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project.
Rietjens JAC, Griffioen I, Sierra-Pérez J, Sroczynski G, Siebert U, Buyx A, Peric B, Svane IM, Brands JBP, Steffensen KD, Romero Piqueras C, Hedayati E, Karsten MM, Couespel N, Akoglu C, Pazo-Cid R, Rayson P, Lingsma HF, Schermer MHN, Steyerberg EW, Payne SA, Korfage IJ, Stiggelbout AM. Rietjens JAC, et al. Among authors: svane im. Palliat Care Soc Pract. 2024 Feb 12;18:26323524231225249. doi: 10.1177/26323524231225249. eCollection 2024. Palliat Care Soc Pract. 2024. PMID: 38352191 Free PMC article.
266 results